Yi-Zhi-Fang-Dai Formula Protects against A β1-42 Oligomer Induced Cell Damage via Increasing Hsp70 and Grp78 Expression in SH-SY5Y Cells

Lumei Liu; Wenbin Wan; Wenjing Chen; Yuanjin Chan; Qi Shen; Yaming Li

doi:10.1155/2016/8591656

Yi-Zhi-Fang-Dai Formula Protects against A β_1-42 Oligomer Induced Cell Damage via Increasing Hsp70 and Grp78 Expression in SH-SY5Y Cells

Evid Based Complement Alternat Med. 2016:2016:8591656. doi: 10.1155/2016/8591656. Epub 2016 Oct 17.

Authors

Lumei Liu¹, Wenbin Wan², Wenjing Chen³, Yuanjin Chan³, Qi Shen⁴, Yaming Li³

Affiliations

¹ Geriatrics Department of Chinese Medicine, Huadong Hospital, Fudan University, Shanghai, China; Department of Integrated Chinese and Western Medicine, Huashan Hospital, Fudan University, Shanghai, China.
² Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai, China.
³ Geriatrics Department of Chinese Medicine, Huadong Hospital, Fudan University, Shanghai, China.
⁴ Shanghai Jiao Tong University School of Pharmacy, Shanghai, China.

Abstract

Yi-Zhi-Fang-Dai formula (YZFDF) is an experiential prescription used to cure dementia cases like Alzheimer's disease (AD). In this study, the main effective compounds of YZFDF have been identified from this formula, and the neuroprotective effect against Aβ_1-42 oligomer of YZFDF has been tested in SH-SY5Y cells. Our results showed that YZFDF could increase cell viability and could attenuate endothelial reticula- (ER-) mediated apoptosis. Evidence indicated that protein folding and endothelial reticula stress (ERS) played an important role in the AD pathological mechanism. We further explored the expression of Hsp70, an important molecular chaperon facilitating the folding of other proteins, and Grp78, the marker protein of ERS in SH-SY5Y cells. Data told us that YZFDF pretreatment could influence the mRNA and protein expression of these two proteins. At last, we also found that YZFDF pretreatment could activate Akt in SH-SY5Y cells. All these above indicate that YZFDF could be a potent therapeutic candidate for AD treatment.